Esperion Therapeutics Announces the Appointment of Gilbert S. Omenn, M.D., Ph.D. to Board of Directors

Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Gilbert S. Omenn, M.D., Ph.D. as a Class II Director, with a term of office expiring in 2015 at the annual meeting of stockholders.

"We are very pleased to welcome Dr. Omenn to the Esperion board of directors,” said Tim Mayleben, president and chief executive officer. “He has a broad range of scientific, research, and policy experience within the healthcare industry that will provide valuable insights as we continue to advance the development of ETC-1002 and expand our product portfolio.”

Dr. Omenn is Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He serves on the Scientific Management Review Board of the National Institute of Health (NIH) and the Community Preventive Services Task Force of the Centers for Disease Control and Prevention (CDC).

Previously, Dr. Omenn served as Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs. He was Professor of Medicine and of Environmental Health, and Dean of the School of Public Health and Community Medicine, at the University of Washington. Dr. Omenn was a member of the intramural program of NIH in the Anfinsen Lab and was a Howard Hughes Investigator with NIH grants spanning four decades. He served previously on the National Cancer Advisory Board, NIH Heart, Lung and Blood Institute Advisory Council, Society of Fellows for the NIH National Center for Minority Health and Health Disparities and on the Director’s Advisory Committee for the CDC. Dr. Omenn earned his Bachelor’s degree summa cum laude from Princeton University, his medical degree magna cum laude from Harvard Medical School, and his Ph.D. in genetics from the University of Washington. Previously, Dr. Omenn has been a member of the board of directors for Amgen Inc. and Rohm & Haas Company.

“As a resident of Ann Arbor with strong ties to the healthcare community both here in Michigan and around the world, I am eager to join the Esperion board,” said Dr. Omenn. “I believe that ETC-1002 has the potential to provide statin intolerant patients with a new and much needed therapeutic alternative to currently available therapies and those in development.”

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed primarily for patients intolerant to statins and with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon the successful and comprehensive Phase 1 and Phase 2a programs. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of ETC-1002, the advancement of the ETC-1002 development program, and the expansion of Esperion’s product portfolio. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion’s filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.